Eye implant for diabetes? study pulled before it began
NCT ID NCT04198350
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This study aimed to transplant insulin-producing cells into the front chamber of the eye for people with type 1 diabetes. The goal was to see if the procedure was safe for the eye. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College London, Imperial College Healthcare NHS Trust
London, W2 1PG, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pancreatic islet cells
What this could lead to
If it had worked, this could point toward a new site for islet transplantation, potentially reducing diabetes complications.
What could go wrong
The study was withdrawn before enrolling anyone, so no data exist. The approach required lifelong immunosuppression and carried risks of eye complications.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.